This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Strategic Partnerships Power Tempus AI's Healthcare Expansion
by Sridatri Sarkar
TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?
by Kinjel Shah
Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights D-Wave Quantum, Rigetti Computing, IonQ, AstraZeneca, AWS and NVIDIA
by Zacks Equity Research
D-Wave, IonQ, and Rigetti post rising revenues, steep losses, and big cash reserves as they race to build scalable quantum systems.
Quantum Stocks Q2 2025: Are D-Wave, IonQ & Rigetti Funding the Future?
by Urmimala Biswas
D-Wave, IonQ and Rigetti post strong Q2 sales, incur steeper losses and have billion-dollar cash reserves to drive quantum breakthroughs.
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
by Zacks Equity Research
AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.
PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?
by Kinjel Shah
Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.
IonQ Stock Surges on Quantum Breakthroughs: More Upside Ahead?
by Urmimala Biswas
IonQ secures major global partnerships and delivers quantum breakthroughs, driving 27% stock gains in three months.
IonQ Secures $1.6 Billion to Power Quantum Projects: Is It a Buy Now?
by Urmimala Biswas
IonQ procures $1B funding to accelerate quantum computing and networking dominance despite near-term losses.
Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season
by Zacks Equity Research
AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates
by Zacks Equity Research
Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
by Zacks Equity Research
Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
by Urmimala Biswas
TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
by Kinjel Shah
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
by Zacks Equity Research
SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
by Zacks Equity Research
Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed
by Zacks Equity Research
MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.
The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk
by Zacks Equity Research
TEM surges 91.8% YTD on rapid AI-healthcare growth, while NVDA fuels the sector with cutting-edge infrastructure and partnerships.
Astrazeneca (AZN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
by Zacks Equity Research
AZN's second-quarter revenues beat on strong drug sales across Oncology and CVRM despite in-line earnings.
Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?
by Urmimala Biswas
Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.